

Grifols awarded Gold Medal by EcoVadis for Sustainability Excellence

- *Grifols ranks among the top 5% of the companies with the best valuation out of 100,000 firms analyzed by EcoVadis worldwide, covering 200 sectors and 175 countries*
- *With a score of 77, Grifols is positioned in the 97th percentile, showcasing its leadership in sustainability*

Barcelona, Spain, Nov. 5, 2024 - Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that it has been awarded a Gold Medal by EcoVadis, a leading global corporate sustainability rating platform, for the second consecutive year.

Achieving a score of 77 out of 100 – an improvement of three points over last year – Grifols now ranks among the top 5% of the more than 100,000 companies evaluated by EcoVadis across 200 sectors and 175 countries.

EcoVadis medals take into account a company's performance over the last year against that of all rated companies in EcoVadis' database. The percentile rank is calculated across all industries and not by each sector individually. Grifols is positioned in the 97th percentile, a distinction underscoring its continuous efforts in environmental stewardship, social responsibility and ethical governance.

This year, Grifols' commitment to sustainable procurement and responsible practices received particular recognition, alongside its strong performance in environmental practices, labor practices and human rights, in addition to ethical leadership.

"This recognition reflects Grifols' steadfast commitment to building a more sustainable and responsible value chain," said Daniel Segarra, VP of Investor Relations and Sustainability at Grifols. "As a healthcare company, we strive not only to enhance patient health but also to reduce our environmental impact while upholding the highest standards of ethics and social responsibility."

EcoVadis evaluates companies across four key pillars: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, benchmarking against international standards such as the UN Global Compact and the Global Reporting Initiative.

For more information on Grifols' ESG initiatives and progress, please visit [Sustainability | Grifols](#) and read more in our [Integrated and Sustainability Annual Report](#).

GRIFOLS

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (Tel. + 34 659 572 185)

Borja_gomez@duomocomunicacion.com

Investors

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different.

GRIFOLS

The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.